3rd Department of Medicine Department of Endocrinology and Metabolism of the 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Applied Biomedical Research Center Basic Sciences Research Institute Mashhad University of Medical Sciences Mashhad Iran

Biotechnology Research Center Pharmaceutical Technology Institute Mashhad University of Medical Sciences Mashhad Iran

Centre for Research Impact and Outcome Chitkara College of Pharmacy Chitkara University Rajpura Punjab 140401 India

Department of Basic Medical Sciences Faculty of Medicine Abadan University of Medical Sciences Abadan Iran

Department of Nutritional Sciences and Dietetics International Hellenic University Thessaloniki 57400 Greece

School of Medicine European University Cyprus Nicosia 2404 Cyprus

Zobrazit více v PubMed

Zhao TJ, Luo D, Jiang X, Tang F, Jiang H. Effect of statins on major adverse cardiovascular events in patients with coronary artery spasm: a meta-analysis of the Asia region. Cardiovasc Ther. 2023. https://doi.org/10.1155/2023/8807278 . PubMed DOI PMC

Banach M, Reiner Ž, Surma S, Bajraktari G, Bielecka-Dabrowa A, Bunc M, et al. 2024 recommendations on the optimal use of lipid-lowering therapy in established atherosclerotic cardiovascular disease and following acute coronary syndromes: a position paper of the International Lipid Expert Panel (ILEP). Drugs. 2024;84(12):1541–77. PubMed DOI PMC

Katsiki N, Giannoukas AD, Athyros VG, Mikhailidis DP. Lipid-lowering treatment in peripheral artery disease. Curr Opin Pharmacol. 2018;39:19–26. PubMed DOI

Katsiki N, P. MD, Banach M. Lipid-lowering agents for concurrent cardiovascular and chronic kidney disease. Expert Opin Pharmacother. 2019;20(16):2007–17. PubMed DOI

Banach M, Surma S, Reiner Z, Katsiki N, Penson PE, Fras Z, et al. Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022). Cardiovasc Diabetol. 2022;21(1):263. PubMed DOI PMC

Aslani S, Razi B, Imani D, Mohammadi K, Jamialah-Madi T, Reiner Ž, et al. Effect of Statins on the blood lipid profile in patients with different cardiovascular diseases: A systematic review with Meta-analysis of randomized clinical trials. Curr Med Chem. 2023;30(32):3702–24. PubMed DOI

Yang XH, Zhang BL, Cheng Y, Fu SK, Jin HM. Statin use and the risk of CVD events, stroke, and all-cause mortality in patients with diabetes: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2022;32(11):2470–82. PubMed DOI

Zahedipour F, Butler AE, Eid AH, Sahebkar A. Pleiotropic properties of statins via angiogenesis modulation in cardiovascular disease. Drug Discov Today. 2022;27(10):103325. PubMed DOI

Aminifar E, Tavakkol Afshari HS, Sathyapalan T, Abbasifard M, Sahebkar A. The pleiotropic effects of statins in rheumatoid arthritis. J Pharm Pharmacol. 2023;75(7):910–20. PubMed DOI

Bohn B, Lutsey PL, Tang W, Pankow JS, Norby FL, Yu B, et al. A proteomic approach for investigating the pleiotropic effects of statins in the atherosclerosis risk in communities (ARIC) study. J Proteomics. 2023. https://doi.org/10.1016/j.jprot.2022.104788 . PubMed DOI

German CA, Liao JK. Understanding the molecular mechanisms of statin pleiotropic effects. Arch Toxicol. 2023;97(6):1529–45. PubMed DOI PMC

Chruściel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, et al. Impact of Statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194–208. PubMed DOI

Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, et al. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021;12(2):237–51. PubMed DOI PMC

Sahebkar A, Foroutan Z, Katsiki N, Jamialahmadi T, Mantzoros CS. Ferroptosis, a new pathogenetic mechanism in cardiometabolic diseases and cancer: is there a role for statin therapy? Metab Clin Exp. 2023. https://doi.org/10.1016/j.metabol.2023.155659 . PubMed DOI

Serban C, Sahebkar A, Ursoniu S, Mikhailidis DP, Rizzo M, Lip GYH, et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep. 2015. https://doi.org/10.1038/srep09902 . PubMed DOI PMC

Mansouri A, Reiner Ž, Ruscica M, Tedeschi-Reiner E, Radbakhsh S, Ekta MB, et al. Antioxidant effects of statins by modulating Nrf2 and Nrf2/HO-1 signaling in different diseases. J Clin Med. 2022. https://doi.org/10.3390/jcm11051313 . PubMed DOI PMC

Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res. 2015;60:50–73. PubMed DOI

Parizadeh SM, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S, et al. Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids. 2011;46(4):333–40. PubMed DOI

Woźniak E, Broncel M, Niedzielski M, Woźniak A, Gorzelak-Pabiś P. The effect of lipid-lowering therapies on the pro-inflammatory and anti-inflammatory properties of vascular endothelial cells. PLoS One. 2023;18(2):e0280741. PubMed DOI PMC

Bahrami A, Parsamanesh N, Atkin SL, Banach M, Sahebkar A. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol Res. 2018;135:230–8. PubMed DOI

Greca E, Kacimi O, Poudel S, Wireko AA, Abdul-Rahman T, Michel G, et al. Immunomodulatory effect of different Statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials. Eur Heart J Cardiovasc Pharmacother. 2023;9(2):122–8. PubMed DOI

Phillip Owens A, Mackman N. The antithrombotic effects of statins. Annu Rev Med. 2014;65:433–45. PubMed DOI

Sahebkar A, Serban C, Mikhailidis DP, Undas A, Lip GY, Muntner P, et al. Association between Statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost. 2015;114(3):546–57. PubMed

Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GYH, et al. The impact of Statin therapy on plasma levels of von Willebrand factor antigen: systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost. 2016;115(3):520–32. PubMed DOI

Liu C, Shen M, Tan WLW, Chen IY, Liu Y, Yu X, et al. Statins improve endothelial function via suppression of epigenetic-driven EndMT. Nat Cardiovasc Res. 2023;2(5):467–85. PubMed DOI PMC

Sahebkar A, Kotani K, Serban C, Ursoniu S, Mikhailidis DP, Jones SR, et al. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis. 2015;241(2):433–42. PubMed DOI

Alidadi M, Montecucco F, Jamialahmadi T, Al-Rasadi K, Johnston TP, Sahebkar A. Beneficial effect of statin therapy on arterial stiffness. Biomed Res Int. 2021. https://doi.org/10.1155/2021/5548310 . PubMed DOI PMC

van Rosendael SE, van den Hoogen IJ, Lin FY, Andreini D, Al-Mallah MH, Budoff MJ, et al. Clinical and coronary plaque predictors of atherosclerotic nonresponse to statin therapy. JACC: Cardiovascular Imaging. 2023;16(4):495–504. PubMed

Mahmoudi A, Katsiki N, Vravblik M, Sahedkar A. Pleiotropic effects of statins: focus on Inflammation, oxidative stress and Immunomodulation (Part I). Curr cardiol rep 2025 pagination details to be added when available.

Kwaifa IK, Bahari H, Yong YK, Noor SM. Endothelial dysfunction in obesity-induced inflammation: molecular mechanisms and clinical implications. Biomolecules. 2020. https://doi.org/10.3390/biom10020291 . PubMed DOI PMC

Gunawardena T, Merinopoulos I, Wickramarachchi U, Vassiliou V, Eccleshall S. Endothelial dysfunction and coronary vasoreactivity - a review of the history, physiology, diagnostic techniques, and clinical relevance. Curr Cardiol Rev. 2021;17(1):85–100. PubMed DOI PMC

Altabas V, Biloš LSK. The role of endothelial progenitor cells in atherosclerosis and impact of anti-lipemic treatments on endothelial repair. Int J Mol Sci. 2022;23(5):2663. PubMed DOI PMC

Chopra H, Hung MK, Kwong DL, Zhang CF, Pow EHN. Insights into endothelial progenitor cells: origin, classification, potentials, and prospects. Stem Cells Int. 2018;2018:9847015. PubMed DOI PMC

Yang JX, Pan YY, Wang XX, Qiu YG, Mao W. Endothelial progenitor cells in age-related vascular remodeling. Cell Transplant. 2018;27(5):786–95. PubMed DOI PMC

Sandhu K, Mamas M, Butler R. Endothelial progenitor cells: exploring the pleiotropic effects of statins. World J Cardiol. 2017;9(1):1–13. PubMed DOI PMC

Gorabi AM, Kiaie N, Hajighasemi S, Banach M, Penson PE, Jamialahmadi T, et al. Statin-induced nitric oxide signaling: mechanisms and therapeutic implications. J Clin Med. 2019. https://doi.org/10.3390/jcm8122051 . PubMed DOI PMC

Morrone D, Picoi MEL, Felice F, De Martino A, Scatena C, Spontoni P, et al. Endothelial progenitor cells: an appraisal of relevant data from bench to bedside. Int J Mol Sci. 2021;22(23):12874. PubMed DOI PMC

Mogharbel BF, Abdelwahid E, Irioda AC, Francisco JC, Simeoni RB, De Souza D, et al. Bone Marrow-Derived stem cell populations are differentially regulated by thyroid or/and ovarian hormone loss. Int J Mol Sci. 2017;18(10):2139. PubMed DOI PMC

Naito T, Shun M, Nishimura H, Gibo T, Tosaka M, Kawashima M, et al. Pleiotropic effect of erythropoiesis-stimulating agents on circulating endothelial progenitor cells in dialysis patients. Clin Exp Nephrol. 2021;25(10):1111–20. PubMed DOI

Balistreri CR, Buffa S, Pisano C, Lio D, Ruvolo G, Mazzesi G. Are endothelial progenitor cells the real solution for cardiovascular diseases? Focus on controversies and perspectives. Biomed Res Int. 2015;2015:835934. PubMed DOI PMC

Chiang KH, Cheng WL, Shih CM, Lin YW, Tsao NW, Kao YT, et al. Statins, HMG-CoA Reductase Inhibitors, Improve Neovascularization by Increasing the Expression Density of CXCR4 in Endothelial Progenitor Cells. PLoS ONE. 2015;10(8).

Cerda A, Fajardo CM, Basso RG, Hirata MH, Hirata RD. Role of MicroRNAs 221/222 on statin induced nitric oxide release in human endothelial cells. Arq Bras Cardiol. 2015;104(3):195–201. PubMed PMC

Meyer N, Brodowski L, Richter K, von Kaisenberg CS, Schröder-Heurich B, von Versen-Höynck F. Pravastatin Promotes Endothelial Colony-Forming Cell Function, Angiogenic Signaling and Protein Expression In Vitro. J Clin Med. 2021;10(2).

Zhang YZ, Wang YT, Koka S, Zhang Y, Hussain T, Li X. Simvastatin improves lysosome function via enhancing lysosome biogenesis in endothelial cells. Front Biosci-Landmark. 2020;25:283–98. DOI

Ait-Aissa K, Leng LN, Lindsey NR, Guo XT, Juhr D, Koval OM, et al. Mechanisms by which statins protect endothelial cells from radiation-induced injury in the carotid artery. Front Cardiovasc Med. 2023;10.

Motoji Y, Fukazawa R, Matsui R, Abe Y, Uehara I, Watanabe M, et al. Statins Show Anti-Atherosclerotic Effects by Improving Endothelial Cell Function in a Kawasaki Disease-like Vasculitis Mouse Model. Int J Mol Sci. 2022;23(24).

António N, Fernandes R, Soares A, Soares F, Lopes A, Carvalheiro T, et al. Impact of prior chronic Statin therapy and high-intensity Statin therapy at discharge on Circulating endothelial progenitor cell levels in patients with acute myocardial infarction: a prospective observational study. Eur J Clin Pharmacol. 2014;70(10):1181–93. PubMed DOI

Ricottini E, Madonna R, Patti G, Grieco D, Zoccoli A, Stampachiacchiere B, et al. Benefit of atorvastatin reload on endothelial progenitor cells in patients on chronic statin treatment undergoing PCI. J Am Coll Cardiol. 2013;61(10):E1635-E. DOI

Ye HH, He FW, Fei XH, Lou YR, Wang SQ, Yang R, et al. High-Dose Atorvastatin reloading before percutaneous coronary intervention increased Circulating endothelial progenitor cells and reduced inflammatory cytokine expression during the perioperative period. J Cardiovasc Pharmacol Therap. 2014;19(3):290–5. DOI

Oikonomou E, Siasos G, Zaromitidou M, Hatzis G, Mourouzis K, Chrysohoou C, et al. Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients. Atherosclerosis. 2015;238(2):159–64. PubMed DOI

Ansheles AA, Rvacheva AV, Sergienko IV. Effect of Atorvastatin Therapy on the Level of CD34 < SUP>+> CD133 < SUP>+ CD309 < SUP>+ Endothelial Progenitor Cells in Patients with Coronary Heart Disease. Bulletin of Experimental Biology and Medicine. 2017;163(1):133-6.

Huang BS, Cheng Y, Xie Q, Lin GX, Wu Y, Feng YL, et al. Effect of 40 mg versus 10 mg of atorvastatin on oxidized low-density lipoprotein, high-sensitivity C-reactive protein, circulating endothelial-derived microparticles, and endothelial progenitor cells in patients with ischemic cardiomyopathy. Clin Cardiol. 2012;35(2):125–30. PubMed DOI PMC

Niu HM, Wei ZZ, Zhang YL, He J, Jia DY. Atorvastatin improves coronary flow and endothelial function in patients with coronary slow flow. Exp Ther Med. 2018;15(1):904–8. PubMed

Baran Ç, Durdu S, Dalva K, Zaim Ç, Dogan A, Ocakoglu G, et al. Effects of preoperative short term use of Atorvastatin on endothelial progenitor cells after coronary surgery: A Randomized, controlled trial. Stem Cell Reviews Rep. 2012;8(3):963–71. DOI

Tousoulis D, Andreou I, Tsiatas M, Miliou A, Tentolouris C, Siasos G, et al. Effects of Rosuvastatin and allopurinol on Circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214(1):151–7. PubMed DOI

Pirro M, Schillaci G, Romagno PF, Mannarino MR, Bagaglia F, Razzi R, et al. Influence of short-term rosuvastatin therapy on endothelial progenitor cells and endothelial function. J Cardiovasc Pharmacol Ther. 2009;14(1):14–21. PubMed DOI

Higashi Y, Matsuoka H, Umei H, Sugano R, Fujii Y, Soga J, et al. Endothelial function in subjects with isolated low HDL cholesterol: role of nitric oxide and Circulating progenitor cells. Am J Physiology-Endocrinology Metabolism. 2010;298(2):E202–9. DOI

Lin LY, Huang CC, Chen JS, Wu TC, Leu HB, Huang PH, et al. Effects of pitavastatin versus atorvastatin on the peripheral endothelial progenitor cells and vascular endothelial growth factor in high-risk patients: a pilot prospective, double-blind, randomized study. Cardiovasc Diabetol. 2014;13.

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin safety and associated adverse events: A scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81.

Singh S, Nguyen HC, Ehsan M, Michels DCR, Singh P, Qadura M, et al. Pravastatin-induced changes in expression of long non-coding and coding RNAs in endothelial cells. Physiological Rep. 2021;9(1).

Shah R, Patel N, Emin M, Celik Y, Jimenez A, Gao S, et al. Statins restore endothelial protection against complement activity in obstructive sleep apnea: A randomized clinical trial. Ann Am Thorac Soc. 2023;20(7):1029–37. PubMed DOI PMC

Boswell-Patterson CA, Hétu M-F, Pang SC, Herr JE, Zhou J, Jain S, et al. Novel theranostic approaches to neovascularized atherosclerotic plaques. Atherosclerosis. 2023;374:1–10. PubMed DOI

Dawson LP, Lum M, Nerleker N, Nicholls SJ, Layland J. Coronary atherosclerotic plaque regression < i > JACC</i > state-of-the-art review. J Am Coll Cardiol. 2022;79(1):66–82. PubMed DOI

Hobson RW, Mackey WC, Ascher E, Murad MH, Calligaro KD, Comerota AJ, et al. Management of atherosclerotic carotid artery disease: clinical practice guidelines of the Society for Vascular Surgery. J Vasc Surg. 2008;48(2):480–6. PubMed DOI

Ma S, Motevalli SM, Chen JW, Xu MQ, Wang YB, Feng J, et al. Precise theranostic nanomedicines for inhibiting vulnerable atherosclerotic plaque progression through regulation of vascular smooth muscle cell phenotype switching. Theranostics. 2018;8(13):3693–706. PubMed DOI PMC

Zahedipour F, Butler AE, Eid AH, Sahebkar A. Pleiotropic properties of statins via angiogenesis modulation in cardiovascular disease. Drug Discovery Today. 2022;27(10).

Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Double-edged role of statins in angiogenesis signaling. Circ Res. 2002;90(6):737–44. PubMed DOI

Ma FX, Han ZC. Statins, nitric oxide and neovascularization. Cardiovasc Drug Rev. 2005;23(4):281–92. PubMed DOI

Koutouzis M, Nomikos A, Nikolidakis S, Tzavara V, Andrikopoulos V, Nikolaou N, et al. Statin treated patients have reduced intraplaque angiogenesis in carotid endarterectomy specimens. Atherosclerosis. 2007;192(2):457–63. PubMed DOI

Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques - implications for plaque stabilization. Circulation. 2001;103(7):926–33. PubMed DOI

Wang ZH, Liu XL, Zhong M, Zhang LP, Shang YY, Hu XY, et al. Pleiotropic effects of Atorvastatin on monocytes in atherosclerotic patients. J Clin Pharmacol. 2010;50(3):311–9. PubMed DOI

Eilenberg W, Stojkovic S, Kaider A, Kozakowski N, Domenig CM, Burghuber C, et al. NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of Statins in patients with carotid atherosclerosis. Clin Chem Lab Med. 2018;56(1):147–56. DOI

Liang X, Yang LX, Guo RW, Shi YK, Hou XH, Yang ZH, et al. Atorvastatin attenuates plaque vulnerability by downregulation of EMMPRIN expression via COX-2/PGE2 pathway. Exp Ther Med. 2017;13(3):835–44. PubMed DOI PMC

Jia F, Wu CF, Chen ZY, Lu GP, Sun JH. Atorvastatin attenuates atherosclerotic plaque destabilization by inhibiting endoplasmic reticulum stress in hyperhomocysteinemic mice. Mol Med Rep. 2016;13(4):3574–80. PubMed DOI

Zeng LP, Liu XF, Yang T, Zhao BM, Tuo HS. Efficacy comparison of rosuvastatin and atorvastatin in the treatment of atherosclerosis and drug safety analysis. Pak J Pharm Sci. 2018;31(5):2203–8.

Mahmoudi A, Atkin SL, Jamialahmadi T, Sahebkar A. Identification of key upregulated genes involved in foam cell formation and the modulatory role of statin therapy. Int Immunopharmacol. 2023;119:110209. PubMed DOI

Zheng S, Du Y, Ye Q, Zha K, Feng J. Atorvastatin enhances foam cell lipophagy and promotes cholesterol efflux through the AMPK/mTOR pathway. J Cardiovasc Pharmacol. 2020.

Karpouzas GA, Papotti B, Ormseth SR, Palumbo M, Hernandez E, Adorni MP, et al. Statins influence the relationship between ATP-binding cassette A1 membrane transporter-mediated cholesterol efflux capacity and coronary atherosclerosis in rheumatoid arthritis. J Transl Autoimmun. 2023;7:100206. PubMed DOI PMC

Ngamdu KS, Ghosalkar DS, Chung HE, Christensen JL, Lee C, Butler CA, et al. Long-term statin therapy is associated with severe coronary artery calcification. PLoS One. 2023;18(7):e0289111. PubMed DOI PMC

Mylonas KS, Peroulis M, Schizas D, Kapelouzou A. MYD88 and proinflammatory chemokines in aortic atheromatosis: exploring novel statin effects. Int J Mol Sci. 2023. https://doi.org/10.3390/ijms24119248 . PubMed DOI PMC

Fici F, Faikoglu G, Tarim BA, Robles NR, Tsioufis K, Grassi G, et al. Pitavastatin: coronary atherosclerotic plaques changes and cardiovascular prevention. High Blood Press Cardiovasc Prev. 2022;29(2):137–44. PubMed DOI

Zhang XH, Chen X, Liang Z, Nie MX, Yan YF, Zhao QM. Pioglitazone combined with atorvastatin promotes plaque stabilization in a rabbit model. Vascular. 2022;30(6):1205–12. PubMed DOI

Huang RZ, Cao Y, Li HR, Hu ZC, Zhang H, Zhang LJ, et al. miR-532-3p-CSF2RA axis as a key regulator of vulnerable atherosclerotic plaque formation. Can J Cardiol. 2020;36(11):1782–94. PubMed

Stasinopoulou M, Kadoglou NPE, Christodoulou E, Paronis E, Kostomitsopoulos NG, Valsami G, et al. Statins’ withdrawal induces atherosclerotic plaque destabilization in animal Model-A rebound stimulation of inflammation. J Cardiovasc Pharmacol Therap. 2019;24(4):377–86. DOI

Du XW, Gao C, Han YW, Liu XX, Wang L, Jiang HJ. Rosuvastatin attenuates the progression of atherosclerotic plaque formation in ApoE. %3CSUP%3E-/-mice. Int J Clin Exp Med. 2017;10(6):9056–64.

Konishi T, Funayama N, Yamamoto T, Hotta D, Nomura R, Nakagaki Y, et al. Stabilization of symptomatic carotid atherosclerotic plaques by statins: a clinico-pathological analysis. Heart Vessels. 2018;33(11):1311–24. PubMed DOI

Chung JW, Hwang J, Lee MJ, Cha J, Bang OY. Previous Statin use and High-Resolution magnetic resonance imaging characteristics of intracranial atherosclerotic plaque the intensive Statin treatment in acute ischemic stroke patients with intracranial atherosclerosis study. Stroke. 2016;47(7):1789–96. PubMed DOI

Oh M, Kim H, Shin EW, Sung C, Kim DH, Moon DH, et al. Effects of ezetimibe/simvastatin 10/10 mg versus rosuvastatin 10 mg on carotid atherosclerotic plaque inflammation. BMC Cardiovasc Disord. 2019. https://doi.org/10.1186/s12872-019-1184-2 . PubMed DOI PMC

Schrör K, Verheugt FWA, Trenk D. Drug-Drug interaction between antiplatelet therapy and Lipid-Lowering agents (Statins and PCSK9 Inhibitors). Thromb Haemost. 2023;123(2):166–76. PubMed DOI

Vavlukis A, Mladenovska K, Davalieva K, Vavlukis M, Dimovski A. Rosuvastatin effects on the HDL proteome in hyperlipidemic patients. Acta Pharm. 2023;73(3):363–84. PubMed DOI

Mann KG. Thrombin generation in hemorrhage control and vascular occlusion. Circulation. 2011;124(2):225–35. PubMed DOI PMC

Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost. 1999;82(08):165–74. PubMed DOI

Giesen P, Rauch U, Bohrmann B, Kling D, Roquè M, Fallon J, et al. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost. 2001;86(01):66–74.

Aoki I, Aoki N, Kawano K, Shimoyama K, Maki A, Homori M, et al. Platelet-dependent thrombin generation in patients with hyperlipidemia. J Am Coll Cardiol. 1997;30(1):91–6. PubMed DOI

Undas A, Brummel KE, Musial J, Mann KG, Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation. 2001;103(18):2248–53. PubMed DOI

Szczeklik A, Musiał J, Undas A, Gajewski P, Góra P, Swadźba J, et al. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. J Am Coll Cardiol. 1999;33(5):1286–93. PubMed DOI

Musiał J, Undas A, Undas R, Brożek J, Szczeklik A. Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels. Thromb Haemost. 2001;85(02):221–5. PubMed DOI

Ferro D, Basili S, Alessandri C, Cara D, Violi F. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis. 2000;149(1):111–6. PubMed DOI

Pastuszczak M, Kotlarz A, Mostowik M, Zalewski J, Zmudka K, Undas A. Prior simvastatin treatment is associated with reduced thrombin generation and platelet activation in patients with acute ST-segment elevation myocardial infarction. Thromb Res. 2010;125(5):382–6. PubMed DOI

Olivotti L, Ghigliotti G, Spallarossa P, Leslie S, Rossettin P, Barsotti A, et al. High doses of atorvastatin do not affect activity of prothrombinase in patients with acute coronary syndromes. Blood Coagul Fibrinolysis. 2002;13(4):315–21. PubMed DOI

Undas A, Celinska-Löwenhoff M, Domagala TB, Iwaniec T, Dropinski J, Löwenhoff T, et al. Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia. Thromb Haemost. 2005;94(07):193–9. PubMed DOI

Undas A, Brummel-Ziedins K, Potaczek DP, Stobierska‐Dzierzek B, Bryniarski L, Szczeklik A, et al. Atorvastatin and Quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost. 2006;4(11):2397–404. PubMed DOI

Ferroni P, Della-Morte D, Pileggi A, Valente M, Martini F, La Farina F, et al. Impact of statins on the coagulation status of type 2 diabetes patients evaluated by a novel thrombin-generation assay. Cardiovasc Drugs Ther. 2012;26:301–9. PubMed DOI

Zolcinski M, Ciesla-Dul M, Undas A. Effects of Atorvastatin on plasma fibrin clot properties in apparently healthy individuals and patients with previous venous thromboembolism. Thromb Haemost. 2012;107(06):1180–2. PubMed DOI

Dahlbäck B. Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders. Int J Lab Hematol. 2016;38(S1):4–11. PubMed DOI

Factor V. Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients. Blood. 2001;98:2423–31.

Undas A, Celinska-Löwenhoff M, Löwenhoff T, Szczeklik A. Statins, fenofibrate, and Quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost. 2006;4(5):1029–36. PubMed DOI

Dujovne CA, Harris WS, Altman R, Overhiser RW, Black DM. Effect of Atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol. 2000;85(3):350–3. PubMed DOI

Nenna A, Nappi F, Lusini M, Satriano UM, Schilirò D, Spadaccio C, et al. Effect of statins on platelet activation and function: from molecular pathways to clinical effects. Biomed Res Int. 2021. https://doi.org/10.1155/2021/6661847 . PubMed DOI PMC

Glynn RJ, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. A randomized trial of Rosuvastatin in the prevention of venous thromboembolism. N Engl J Med. 2009;360(18):1851–61. PubMed DOI PMC

Wells PS, Gebel M, Prins MH, Davidson BL, Lensing AW. Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving Rivaroxaban or standard anticoagulant therapy. Thromb J. 2014;12:1–7. DOI

Antoniou T, Macdonald EM, Yao Z, Hollands S, Gomes T, Tadrous M, et al. Association between Statin use and ischemic stroke or major hemorrhage in patients taking Dabigatran for atrial fibrillation. CMAJ. 2017;189(1):E4–10. PubMed DOI PMC

Goldstein L, Amarenco P, Szarek M, Callahan IIIA, Hennerici M, Sillesen H, et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology. 2008;70(24_part_2):2364–70. PubMed DOI

Ambrosi P, Aillaud M-F, Habib G, Kreitmann B, Métras D, Luccioni R, et al. Fluvastatin decreases soluble thrombomodulin in cardiac transplant recipients. Thromb Haemost. 2000;83(01):46–8. PubMed DOI

Esmon CT. The Protein C Pathway. Chest. 2003;124(3, Supplement):26S-32S. PubMed DOI

Siniscalchi C, Basaglia M, Riva M, Meschi M, Meschi T, Castaldo G, et al. Statins effects on blood clotting: A review. Cells. 2023;12(23):2719. PubMed DOI PMC

Huang B, Han X, Pan Y, Chen D. A systematic review and meta-analysis of the effect of high-intensity statin on coronary microvascular dysfunction. BMC Cardiovasc Disord. 2023;23(1):370. PubMed DOI PMC

Lee M, Choi WJ, Lee Y, Lee K, Park M-W, Myong J-P, et al. Association between Statin therapy and mortality in patients on Dialysis after atherosclerotic cardiovascular diseases. Sci Rep. 2023;13(1):10940. PubMed DOI PMC

Bea S, Oh IS, Kim JH, Sinn DH, Chang Y, Ryu S, et al. High-Intensity Statin reduces the risk of mortality among chronic liver disease patients with atherosclerotic cardiovascular disease: A Population-Based cohort study. J Am Heart Assoc. 2023;12(8):e028310. PubMed DOI PMC

Liu T, Zuo R, Wang J, Huangtao Z, Wang B, Sun L, et al. Cardiovascular disease preventive effects of aspirin combined with different statins in the United States general population. Sci Rep. 2023;13(1):4585. PubMed DOI PMC

Feng T, Li Y, Xue X, Yang W, Li Q, Huang Y, et al. Association of statin use and increase in lipoprotein(a): a real-world database research. Eur J Med Res. 2023;28(1):212. PubMed DOI PMC

Yeoh A, Cheung R, Ahmed A, Chitnis AS, Do A, Wong RJ. Cardiovascular disease risk and statin use among adults with metabolic dysfunction associated fatty liver disease. Am J Med. 2023;136(7):669-76.e1. PubMed DOI

Katsiki N, Kolovou G, Vrablik M. Metabolic dysfunction Associated-Steatotic liver disease (MASLD) and cardiovascular risk: embrace all facets of the disease. Curr Cardiol Rep. 2025;27(1):19. PubMed DOI

Katsiki N, Filippatos T, Vlachopoulos C, Panagiotakos D, Milionis H, Tselepis A, et al. Executive summary of the Hellenic atherosclerosis society guidelines for the diagnosis and treatment of dyslipidemias – 2023. Atherosclerosis Plus. 2024;55:74–92. PubMed DOI PMC

Kokkorakis M, Boutari C, Katsiki N, Mantzoros CS. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need. Metabolism. 2023;147:155664. PubMed DOI

Katsiki N, Perez-Martinez P, Anagnostis P, Mikhailidis DP, Karagiannis A. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome? Curr Vasc Pharmacol. 2018;16(3):219–27. PubMed DOI

Katsiki N, Mikhailidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109–23. PubMed DOI

Tacke F, Horn P, Wong VW-S, Ratziu V, Bugianesi E, Francque S, et al. EASL–EASD–EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary. Diabetologia. 2024;67(11):2375–92. DOI

Lee S, Lee N, Shin S-J. Relationship of missed statin therapy and 10-year atherosclerotic cardiovascular disease risk score to retear rate after arthroscopic rotator cuff repair. Am J Sports Med. 2023;51(8):1988–96. PubMed DOI

Oh GC, Lee KY, Choo EH, Hwang BH, Chung WS, You SJ, et al. Role of statins after endovascular repair of abdominal aortic aneurysms: a nationwide population-based study. J Clin Med. 2023. https://doi.org/10.3390/jcm12113737 . PubMed DOI PMC

Fiore V, Barucca A, Barraco S, Triggiani D, Tragni D, Piazzolla G, et al. Dyslipidemia and cardiovascular prevention in the elderly: a balance between benefits and risks of statin treatment in a specific population. Endocrine, Metabolic & Immune Disorders. 2023;23(11):1371–9. DOI

Sadeghdoust M, Aligolighasemabadi F, Dehesh T, Taefehshokr N, Sadeghdoust A, Kotfis K, et al. The effects of Statins on respiratory symptoms and pulmonary fibrosis in COVID-19 patients with diabetes mellitus: A longitudinal multicenter study. Arch Immunol Ther Exp (Warsz). 2023;71(1):8. PubMed DOI

Torres-Peña JD, Katsiki N, Perez-Martinez P. Could statin therapy be useful in patients with coronavirus disease 2019 (COVID-19)? Front Cardiovasc Med. 2021;8:775749. PubMed DOI PMC

Katsiki N, Banach M, Mikhailidis DP. More good news on statins and COVID-19. Am J Cardiol. 2021;138:127–8. PubMed DOI

Chen X, Hu F, Chai F, Chen X. Effect of statins on pulmonary function in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials. J Thorac Dis. 2023;15(7):3944–52. PubMed DOI PMC

Reimers A, Odin P, Ljung H. Drug-induced cognitive impairment. Drug Saf. 2025;48(4):339–61. PubMed DOI

Yang Z, Wang H, Edwards D, Ding C, Yan L, Brayne C, et al. Association of blood lipids, atherosclerosis and statin use with dementia and cognitive impairment after stroke: a systematic review and meta-analysis. Ageing Res Rev. 2020;57:100962. PubMed DOI

Adhikari A, Tripathy S, Chuzi S, Peterson J, Stone NJ. Association between statin use and cognitive function: a systematic review of randomized clinical trials and observational studies. J Clin Lipidol. 2021;15(1):22-e3212. PubMed DOI

Chadha B, Frishman WH. Review of the Protective Effects of Statins on Cognition. Cardiol Rev. 2021;29(6).

Alsubaie N, Al-Kuraishy HM, Al-Gareeb AI, Alharbi B, De Waard M, Sabatier JM, et al. Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci. 2022. https://doi.org/10.3390/brainsci12101290 . PubMed DOI PMC

Katsiki N, Genovefa K, Pablo P-M, Mikhailidis DP. Dyslipidaemia in the elderly: to treat or not to treat? Expert Rev Clin Pharmacol. 2018;11(3):259–78. PubMed DOI

Wettermark B, Kalantaripour C, Forslund T, Hjemdahl P. Statin treatment for primary and secondary prevention in elderly patients—a cross-sectional study in Stockholm, Sweden. Eur J Clin Pharmacol. 2024;80(10):1571–80. PubMed DOI PMC

Katsiki N, Triposkiadis F, Giannoukas AD, Mikhailidis DP. Statin loading in cardiovascular surgery: never too early to treat. Curr Opin Cardiol. 2018;33(4):436–43. PubMed DOI